$RPD

3 Stocks That May Be Trading Below Their Estimated Value

This article identifies three U.S. stocks—Rapid7 (RPD), Allot (ALLT), and Privia Health Group (PRVA)—that appear to be trading below their estimated fair value based on discounted cash flow analysis, presenting potential opportunities for investors. Despite varied financial profiles, each company shows promising earnings growth forecasts. The piece encourages investors to explore these undervalued options for long-term growth prospects in a fluctuating market.

Original reporting
Simply Wall Street · Simply Wall St
Published Jan 1, 2026, 9:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 1, 2026, 9:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
3 Stocks That May Be Trading Below Their Estimated Value — source image
Decision brief

The 30-second read

$RPDBullishMed
01

Why it matters

If market perceptions align, these stocks could experience price corrections upward, benefiting long-term investors.

02

Market read

The stocks are relevant within the software and healthcare sectors, with potential for growth if undervaluation persists.

03

What to watch

Macroeconomic factors, competitive landscape, and upcoming earnings releases could influence stock performance.

Timing: Moderate; analysis suggests medium-term investment opportunities.

Background

The article highlights undervalued stocks based on discounted cash flow analysis, suggesting potential investment opportunities.

Company-level read

Ticker impact

$RPDBullishMedium confidence
Context

High relevance due to positive sentiment and undervaluation indication.

Expected impact

Potential moderate increase in stock price over the next 6-12 months, estimated 10-15% upside.

Evidence & confidence

The valuation suggests undervaluation; however, market volatility and company-specific risks warrant cautious optimism.

$ALLTNeutralMedium confidence
Context

Moderate relevance; no specific sentiment data provided, but identified as undervalued.

Expected impact

Possible modest appreciation, around 5-10% over the next year.

Evidence & confidence

Valuation indicates potential undervaluation, but lack of sentiment data limits confidence.

$PRVANeutralLow confidence
Context

Low relevance; no sentiment data available, and less emphasis in the analysis.

Expected impact

Uncertain; likely minimal immediate price movement.

Evidence & confidence

Insufficient data and lower relevance scores diminish actionable insights.

Market effects

Potential positive impact on cybersecurity and software sectors due to undervaluation of key stocks.

Limited regional impact; focused on U.S. stocks.

Low; specific to U.S. market and sectors.

Counterpoint

The stocks may be undervalued due to temporary market disruptions or company-specific issues; potential for further decline exists.

Key entities

  • Rapid7

    Cybersecurity and data analytics firm.

  • Allot

    Provider of network analytics and security solutions.

  • Privia Health Group

    Healthcare technology and services provider.

Related articles

$PRVAHighAI 9/10

Privia Health Group, Inc. (PRVA): Results of Operations and Financial Condition

Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for

$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

$RPDMedAI 8/10

Rapid7 (RPD) Stock Trades Down, Here Is Why

Rapid7 (NASDAQ: RPD) shares fell 11.3% in the morning after Morgan Stanley downgraded the stock from Equal Weight to Underweight and kept a $9 price target. The firm cited competitive pressure in vulnerability management from AI-focused rivals and said Rapid7 has lagged in exposure management and real-time remediation. RPD is down 26.5% YTD.

$RPDMedAI 8/10

Rapid7 (RPD) Releases Findings of Q1 Threat Landscape Report

Rapid7 (NASDAQ:RPD) released its Q1 2026 Threat Landscape Report on May 21, citing vulnerability exploitation as 38% of incident response cases. The company said AI is speeding attackers’ ability to identify and exploit unpatched systems. Separately, Barclays lowered its price target and kept an Underweight rating after Rapid7’s Q1 results, citing weaker-than-expected Q2 ARR guidance. Rapid7 projects Q2 ARR of about $820M versus $832M in Q1.